{
    "clinical_study": {
        "@rank": "43382", 
        "arm_group": [
            {
                "arm_group_label": "triamcinolone injection (10 mg/ml)", 
                "arm_group_type": "Active Comparator", 
                "description": "Three finger nails are chosen from the equally average Targeted NAPSI scores which are evaluated by two independent dermatologists. Block randomization are performed to arrange such fingers into group A, B or C\nGroup A:  Triamcinolone injection (10 mg/ml) on 4 sites for the pathology from both nail matrix (B) and nail bed (A) or 2 sites for the pathology from either nail matrix(B)  or nail bed (A) as shown in picture, the EMLA was applied before injection"
            }, 
            {
                "arm_group_label": "Topical 0.05% clobetasol ointment", 
                "arm_group_type": "Active Comparator", 
                "description": "Three finger nails are chosen from the equally average Targeted NAPSI scores which are evaluated by two independent dermatologists. Block randomization are performed to arrange such fingers into group A, B or C Apply Topical 0.05% clobetasol propionate ointment on the nail fold twice daily for 6 months"
            }, 
            {
                "arm_group_label": "Controlled group", 
                "arm_group_type": "No Intervention", 
                "description": "Three finger nails are chosen from the equally average Targeted NAPSI scores which are evaluated by two independent dermatologists. Block randomization are performed to arrange such fingers into group A, B or C Controlled group"
            }
        ], 
        "brief_summary": {
            "textblock": "Psoriatic nails can significantly affect a quality of life of patients. Psoriasis affects\n      both nail matrix and nail bed. Pitting, leukonychia and red spots in lunula indicate a\n      defect in the nail matrix. Psoriasis can change the nail bed as the results in onycholysis,\n      discoloration, splinter hemorrhage and subungual hyperkeratosis. The main treatment of\n      psoriatic nails is using topical high- potent steroids however topical steroids are limited\n      their ability to penetrate deep nail matrix or nail bed which are the main pathology. Use of\n      such a treatment can lead to skin atrophy and report in the case of \"Disappearing digits\".\n      Previous studies of steroid injection in the treatment of psoriatic nails show satisfactory\n      results without any serious permanent adverse effects. At present, there is no comparison\n      study between intralesional steroid and ultrapotent topical steroid for the treatment of\n      psoriatic nails.\n\n      The purpose of the study is to evaluate the efficacy and safety of intralesional\n      triamcinolone comparing to 0.05% clobetasol ointment in the treatment of psoriatic nails."
        }, 
        "brief_title": "Comparison of Efficacy of Intralesional Triamcinolone Injection and Clobetasol Propionate Ointment for Psoriatic Nails", 
        "completion_date": {
            "#text": "June 2012", 
            "@type": "Actual"
        }, 
        "condition": "Psoriatic Nails", 
        "detailed_description": {
            "textblock": "Psoriasis is a chronic inflammatory disorder. The nails involvement has been reported up to\n      40% of psoriatic patients. Psoriatic nails can significantly affect a quality of life of\n      patients. Psoriasis affects both nail matrix and nail bed. Pitting, leukonychia and red\n      spots in lunula indicate a defect in the nail matrix. Psoriasis can change the nail bed as\n      the results in onycholysis, discoloration, splinter hemorrhage and subungual hyperkeratosis.\n      The main treatment of psoriatic nails is using topical high- potent steroids however topical\n      steroids are limited their ability to penetrate deep nail matrix or nail bed which are the\n      main pathology. Use of such a treatment can lead to skin atrophy and report in the case of\n      \"Disappearing digits\". Previous studies of steroid injection in the treatment of psoriatic\n      nails show satisfactory results without any serious permanent adverse effects. At present,\n      there is no comparison study between intralesional steroid and ultrapotent topical steroid\n      for the treatment of psoriatic nails.\n\n      The purpose of the study is to evaluate the efficacy and safety of intralesional\n      triamcinolone comparing to 0.05% clobetasol ointment in the treatment of psoriatic nails."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects aged over 18 years old who have at least 3 psoriatic finger nails resembly\n             severity\n\n        Exclusion Criteria:\n\n          1. Patients are receiving the systemic therapy of psoriasis\n\n          2. Patients discontinued the systemic therapy less than 3 months and topical therapy\n             less than 1 month\n\n          3. Positive results for the microscopic study of fungus in finger nails\n\n          4. History of steroids or EMLA allergy\n\n          5. Pregnancy or nursing\n\n          6. Any skin infection at the site of the treatment\n\n          7. Human immunodeficiency virus subjects\n\n          8. History of malignancy or during the treatment of malignancy\n\n          9. Patients who have psychological disorder\n\n         10. Patients who have bleeding disorder or receiving anticoagulation drugs"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "16", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 15, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01703325", 
            "org_study_id": "Si599/2010"
        }, 
        "intervention": {
            "arm_group_label": [
                "triamcinolone injection (10 mg/ml)", 
                "Topical 0.05% clobetasol ointment"
            ], 
            "description": "Three finger nails are chosen from the equally average NAPSI scores which are evaluated by two independent dermatologists. Block randomization are performed to arrange such fingers into group A, B or C\nGroup A:  Triamcinolone injection (10 mg/ml) on 4 sites for the pathology from both nail matrix (B) and nail bed (A) or 2 sites for the pathology from either nail matrix(B)  or nail bed (A) as shown in picture, the EMLA was applied before injection\nGroup B:  Apply Topical 0.05% clobetasol propionate ointment (Dermovate\u00ae) on the nail fold twice daily for 6 months\nGroup C:  Controlled group", 
            "intervention_name": "0.1% triamcinolone , 0.05% clobetasol propionate ointment", 
            "intervention_type": "Drug", 
            "other_name": "Dermovate ointment"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Triamcinolone hexacetonide", 
                "Clobetasol", 
                "Triamcinolone", 
                "Triamcinolone Acetonide", 
                "Triamcinolone diacetate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Psoriatic nails", 
            "Triamcinolone injection", 
            "clobetasol propionate"
        ], 
        "lastchanged_date": "October 7, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Bangkok", 
                    "country": "Thailand", 
                    "zip": "10700"
                }, 
                "name": "Siriraj Hospital"
            }
        }, 
        "location_countries": {
            "country": "Thailand"
        }, 
        "number_of_arms": "3", 
        "official_title": "Comparison of Efficacy and Safety of Psoriatic Nails Treatment Between by Intralesional 0.1%Triamcinolone Injection and Topical 0.05%Clobetasol Propionate Ointment", 
        "overall_official": {
            "affiliation": "Faculty of Medicine Siriraj Hospital", 
            "last_name": "Chanisada Wongpraparut, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Thailand: Ethical Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "1.\tTo compare the percent change in the NAPSI (Nail Psoriasis Severity Index) score of Psoriatic nails after treatment with intralesional 0.1%triamcinolone injection vs.topical 0.05% clobetasol propionate ointment and controlled untreated group.", 
            "measure": "Percent change in the NAPSI (Nail Psoriasis Severit Index) score of psoriatic nails after treatment with intralesional 0.1%triamcinolone injection vs.topical 0.05% clobetasol propionate ointment", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01703325"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Mahidol University", 
            "investigator_full_name": "chanisada tuchinda", 
            "investigator_title": "Assistant Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Observe the possible adverse effects of the intralesional steroid injection and topical 0.05% clobetasol propionate ointment treatment for psoriatic nails.", 
            "measure": "adverse effects of the intralesional steroid injection and topical 0.05% clobetasol propionate ointment", 
            "safety_issue": "Yes", 
            "time_frame": "6 months"
        }, 
        "source": "Mahidol University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mahidol University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2010", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}